CMBA
ESPR

C.M. Bidwell & Associates’s Esperion Therapeutics ESPR Stock Holding History

C.M. Bidwell & Associates’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$1.11K – 495
2025
Q4 		$1.11K Hold
300
– – ﹤0.01% 419
2025
Q3 		$795 Buy
+300
New +$580 ﹤0.01% 439
2017
Q2 		– Sell
-6,205
Closed -$219K – 338
2017
Q1 		$219K Sell
6,205
-9,855
-61% -$226K 0.05% 145
2016
Q4 		$201K Hold
16,060
– – 0.05% 159
2016
Q3 		$222K Buy
+16,060
New +$182K 0.05% 150

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's ESPR Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 300 shares — an estimated $1.11K sold.

C.M. Bidwell & Associates first reported a position in ESPR in Q3 2016 and held it in 5 quarters. The position peaked at $222K in Q3 2016. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • C.M. Bidwell & Associates reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 300 Esperion Therapeutics shares in Q1 2026, an estimated $1.11K.
  • C.M. Bidwell & Associates first reported a position in Esperion Therapeutics in Q3 2016 and held it in 5 quarters.
  • C.M. Bidwell & Associates's Esperion Therapeutics position peaked at $222K in Q3 2016.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.